NLRP3 and colitis: As for wogonoside (12.5, 25 or 50 mg/kg), its application inhibits the activation of NF-κB-induced NLRP3 inflammasomes in DSS-induced colitis and colitis-associated tumorigenesis in mice [48, 49].